Together, these data suggest that the WNT modifying pseudokinases ROR2 and RYK represent potential novel therapeutic targets for neuroblastoma treatment and that current research on immuno-therapeutic strategies against ROR1 might need to be re-evaluated in favor of ROR2 and RYK. The gene discussed is RYK; the disease is neuroblastoma.